Popular search terms:
Search Results Label
79 results found-
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...ping-2017-2018-influenza-vaccines -
Seqirus Releases Real-World Data Indicating Significantly Greater
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...based-seasonal-influenza-vaccines -
Seqirus Announces U.S. $140 Million Manufacturing Expansion to
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
https://www.seqirus.com/...0-million-manufacturing-expansion -
JCVI advocates adjuvanted influenza vaccine for patients aged
This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu season in the UK.
https://www.seqirus.com/...ates-adjuvanted-influenza-vaccine -
First cell-based quadrivalent influenza vaccine approved for
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...luenza-vaccine-approved-in-europe -
Seqirus | Partnership Opportunities
Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.seqirus.com/partnering -
Seqirus announces next major advancement in cell-based influenza
In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.
https://www.seqirus.com/...ased-influenza-vaccine-technology -
Seqirus | Research & Development Efforts
Seqirus is working tirelessly to optimise our technology and implement transformational long-term approaches to influenza pandemic preparedness.
https://www.seqirus.com/r-and-d -
Seqirus | Vaccine Technologies
Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.
https://www.seqirus.com/manufacturing/technologies -
Seqirus | Technical Development
Understand our aim to develop the next generation of influenza vaccines and how we're working to unite product platforms across the globe.
https://www.seqirus.com/manufacturing/technical-development